This conversation is particularly important for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), as these represent absolute contraindications to the use of products with the thyroid C-cell tumor boxed warning, including semaglutide, liraglutide, dulaglutide, exenatide extended-release, and tirzepatide
FDA in June 2019, but only for women with acquired, generalized HSDD (Hypoactive Sexual Desire Disorder)
Over time usually about three months many patients experience weight loss that is sustainable, as long as they work with their naturopath to find nutrition and exercise approaches they can continue long term
If you are at risk of developing diabetes, high blood pressure, heart disease, all these things that obesity can contribute to, then I would argue that its not a good thing, but its not about shaming. Public health approach Sceppa stresses that while GLP-1 medications can drive weight loss, they also come with trade-offs